{‘She lacks little experience’: this American scientific community girds for Høeg's tenure at the FDA.

While the United States continues making historic adjustments to its vaccination recommendations, one figure has emerged unexpectedly: Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines throughout the global health crisis and has zeroed in on alleged fatalities following COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Vaccine Program

Public health authorities planned to unveil radical changes to the pediatric vaccine schedule recently, synchronizing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US out of step with much of the world with no evidence for benefit. The planned update has been postponed until the new year.

In place of the top vaccines chief, Dr. Høeg is set to speak at the meeting. She was just designated acting director of the FDA’s CDER, the fifth person to head the office this calendar year.

Consolidating Power at the FDA

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting certain childhood shot schedules in the US to become more similar to Denmark's approach, a society with comprehensive healthcare and a population approximately the population of Wisconsin’s.

So far statements, she has kept her attention on vaccines – typically the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Qualifications

Dr. Høeg has little discernible track record in drug development, oversight or management, which has been standard for former directors of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a major agency. She is not an expert in drug approvals.”

Past directors of CBER would “be deeply familiar with legal statutes and the science of drug development”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

CDER has an vast portfolio at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the new drug program, but the generic program authorizes numerous generic medications. There is also a biosimilars program, over-the-counter program and other areas, and all of those must be managed,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a substantial management element to the position, which manages more than 5,000 employees. “It’s a massive management job, if you execute it properly,” Woodcock added.

Agency Reaction and Contentious Initiatives

When asked about concerns about Dr. Høeg's credentials and whether this appointment indicates greater collaboration among FDA leaders on vaccines, a spokesperson stated that the “questions are based on incorrect assumptions”.

“This background matches the duties of her job,” the official said, noting the period Høeg spent advising the agency head on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a disputed one-day drug-approval program that allegedly concerned her preceding directors. “How are these drugs being selected for this expedited pathway? Who is making the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, with the exception of vaccines.”

Documented Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if problematic, track record, some experts observe. She authored a analysis using unverified public submissions to determine the rate of heart inflammation after COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are riskier than they are.

Among her “desired changes” for the current administration encompassed altering guidelines for new vaccines and ending “non-essential” vaccines, she stated following the vote on a audio program. At the agency, Høeg has according to sources suggested preventing young men from obtaining Covid vaccines.

“She’s an all-around ideologue who starts off with her conclusions and tailors the evidence to retrofit the evidence in a highly deceptive, untruthful fashion,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|